According to a meta-analysis of 11 phase 2 randomized controlled trials, the treatment regimen with a GLP-1 receptor agonist (liraglutide or semaglutide) for a median of 26 weeks was strongly associated with significant reductions in LFC, as well as increased histological resolution of NASH without worsening of fibrosis, compared to the placebo or reference therapy group [154]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.